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Abstract 
Folate, important cofactorin one carbon moiety transfer, has been a factor that may modulate the development of 
colorectal cancer through aberrant DNA methylation and altered nucleotide synthesis and repair. Major folate transport 
across cell membrane is mediated by reduced folate carrier-1 (RFC1) that also preferably transports chemotherapeutic 
agents. Variants within the RFC 1 by influencing folate uptake may lead to colorectal cancer susceptibility. Our study is 
the first to investigate prospectively the RFC gene polymorphism in colorectal cancer in Kashmiri population. A total of 
620 subjects (300 colorectal cancer patients and 320 normal subjects) were analyzed by PCR-RFLP technique for RFC 
gene polymorphism in exon 2 at position 80. We observed 1.27 fold increased risk for AA homozygous variant (OR= 
1.27; 95% CI, 0.8678 - 1.875) and 1.19 fold increased risk for GA heterozygous genotypes (OR= 1.19; 95% CI, 0.8080 - 
1.760) respectively to CRC susceptibility. However the statistically significant results for smoking and tumor location 
characteristics were stratified with RFC1 polymorphism, which suggests a possible effect of smoking and cancer location 
in the etiology of CRC in Kashmir.  
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1. Introduction 
Folate (an essential micronutrient in humans) has important biological function of providing single carbon units (methyl 
groups) required for intracellular methylation reactions and de novo DNA and amino acid metabolism, through folate 
metabolism pathway. Such importance suggests that folate deficiency [1, 2] and polymorphic variants in genes 
metabolizing it may modulate risk of colorectal cancer through aberrant DNA methylation and altered nucleotide 
synthesis and repair.  
From various contradictory studies, dual role of folate has been hypothesized [3, 4, 5], which is, that folate deficiency in 
normal colorectal tissues may promote carcinogenesis, while as deficiency of folate could pose an inhibitory effect on 
the progression of established neoplasms [6, 3]. As folates (hydrophilic anionic molecules) cannot cross cell membranes 
by diffusion alone so require membrane transport systems for cellular uptake [7]. RFC (reduced folate carrier) is the 
major transport system in mammalian cells for folate, actively transports folate compounds into cells from the plasma 
and plays a role in maintaining intracellular concentrations of folate [7]. This saturable anion dependent membrane 
carrier appears to function optimally at physiological pH [8]. It has a greater affinity for reduced folates like 5-methyl 
THF and 5-formyl THF (Km = 1 - 5 μM) and is ubiquitously expressed in normal epithelial cells and cancer of epithelial 
origin [9, 10]. 
In addition to its role in folate uptake, RFC1 has a critical role in homeostasis of folate in mammalian cells, where its 
down regulation occurs as a response to folate deficiency [11]. Although a number of studies have examined the effect of 
single point mutations on RFC protein stability and function [12, 13], little is known about the mechanism of folate 
translocation into the cell. The RFC system also mediates internalization of antifolates including methotrexate (MTX) 
used to treat cancers, into cells [14,15]. Membrane transport of anti-folates by RFC is essential to the chemotherapeutic 
activity of such drugs, providing optimal intracellular drug concentrations to enable inhibition of target enzymes [16]. 
Therefore genetic variations in the gene may affect the transport of these drugs too [17]. Indeed, decreased RFC function 
results in resistance to anti-folate agents [15].This anion exchanging concentrative process is opposed by independent 
exit pumps that are directly coupled tometabolism of energy. These balanced processes inturngoverns the free 
intracellular folate level. 
A common non-synonymous SNP Arg27His (80G>A; rs1051266 found across all ethnic groups is the most extensively 
studied variant of the RFC1 gene, in exon 2 that results in substitution of a histidine for an arginine at residue 27 in the 
protein sequence [18]. This variant has been widely studied for its function in transport uptake as well as its association 
with risk to cancers and drug response and toxicity. It was also suggested that the location of the RFC 80 G>A 
polymorphism in a region important to substrate binding might affect folate transport [19]. Alterations in folate 
membrane transport by RFC may be further compounded by gene polymorphisms that result in changes in the catalytic 
activities of folate-dependent interconverting and biosynthetic enzymes such as 5,10-methylene tetra hydro folate 
reductase (MTHFR) that impact the intracellular distribution of individual reduced folate forms [20]. The genotype 
frequencies for the RFC show marked geographic and ethnic variation, and this can in turn modulate the cancer risk in 
different geographical regions depending on the folate intake [21].The associations between RFC gene 80G>A 
polymorphism and CRC risk has been investigated in several previous studies [21-29]. 
Kashmir with distinct cultural, socio-economic and lifestyle trends, has been reported as a high incidence area of GIT 
cancers [30, 31]. In Kashmir valley, CRC is the third most common GIT cancer [32, 33]. Most of the work done in 
Kashmir has primarily focused on upper GIT cancers [30, 34]. and inspite of a high incidence CRC [32, 33], this area has 
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been undermined. In light of this, we designed a prospective, case-control study in a homogeneous sample of 620 
individuals (300 cases and 320 controls). The aim was to investigate -i) the polymorphic spectrum of crucial folate 
transporting RFC gene in the ethnic population ii) to associate the possible risk, if any, of these polymorphisms withCRC 
susceptibility and iii) to associate various CRC risk factors in these patients with the disease susceptibility.  
2. Materials and Method  
2.1. Study population 
The study was carried out in the Department of Biochemistry, University of Kashmir, in collaboration with the 
Department of General Surgery, at Sher-i- Kashmir Institute of Medical Science (SKIMS) Hospital, Srinagar, from 
where patients were recruited over a period of 4 years, following proper approval. The diagnosis of CRC was based on 
the standard colonoscopic/sigmoidoscopic methods (flexible type) and histopathological criteria. Controls (matched to 
cases by gender, age)were taken from healthy individuals of Kashmir valley from same division showing no clinical 
evidence suggestive of presence of CRC or any other bowel related diseases that might affect the study. Informed 
consent was obtained from each subject and personal data from each participant regarding demographic characteristics, 
such as sex, age, and related risk factors including smoking were collected via questionnaire. 3ml of venous blood 
sample was obtained from each subject and then immediately shifted and stored at -80°C until DNA was extracted. 
Present study included a total of 300 colonoscopically and histologically confirmed CRC patients as cases and 320 
healthy malignancy free individuals as controls. Commercially available, genomic DNA purification kit (Genetix 
Biotech Asia, Pvt Ltd.) was used to extract the DNA from the blood samples of Subjects both cases and controls.  
2.2. Genotyping  
Desired region of the genome was amplified using the specific primer set consisting of RFC1- Forward: 5'-
AGTGTCACCTTCGTCCC-3' and Reverse: 5'- TCCCGCGCGTGAAGTTCTTG-3' sequences that resulted in the 
amplification of 230 bp fragment. PCR was carried out in a final volume of 25μl reaction mixture that consisted of 50-75 
ng of genomic DNA template, 0.5μM of each primer(Genescript), 12.5μl of Maxima Hot start master mix (Fermentas/ 
Thermoscientific) (along with nuclease free water added accordingly). The conditions were selected after extensively 
standardizing all the parameters. PCR technique applied to amplify the polymorphic site of RFC1, consisted of an initial 
denaturation for 2 min, followed by 35 cycles each of 30s at 94oC, 30s annealing phase at 52oC and 45s extension phase 
at 72oC and ultimately a 7 min final extension at 72oC was used to complete the reaction. The A-to-G transition at 
position 80 creates a HhaI (GCG/C) restriction site, amplicons were treated with HhaI (Fermentas) (1U at 37oC) enzyme 
and kept for 3 hours which resulted in three fragments of 125, 68, and 37 bp, in the presence of the 80G allele, while the 
80A allele produced two fragments of 162 and 68 bp. These were then electrophorised on ethidium bromide treated 3% 
agarose gel (Sigma Aldrich).  
3. Statistical Analysis  
GraphPad Prism version 6.0, softwarewas used to carry out the statistical analysis on the data.Results were expressed as 
means ± Standard deviation. Values of p<0.05 were considered to indicate statistical significance. Expected genotype 
frequencies were calculated from allele frequencies under the assumption of Hardy-Weinberg equilibrium. The 
differences in allele frequencies between cases and control were determined using chi-square test .The interaction 
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between RCF1 genotypes was evaluated by calculating the odds ratios (OR) for mutant genotypes, as compared to wild 
types. 95% confidence intervals (95% CI) were calculated to estimate the risk of the different genotypes. 
4. Results 
Present study included a total of 165 male and 135 female cases (M/F ratio-1.22); and 167 male and 153 female (M/F 
ratio- 1.09) control subjects. Table 1 presents selective general characteristics of cases and controls that were included in 
the present study. Mean age of cases was found to be 54.40 ± 13.45 (SD) while as in controls it was 53.80 ± 13.25 (SD). 
Since no significant differences were observed between cases and controls with respect to various characteristics 
(p>0.05), it suggested that frequency matching was adequate. 
Table 1. General Characteristics of Study Population (cases and controls) 
  Variables Cases   (n=300) 
n                  (%) 
Controls  (n=320)  
n                   (%) 
p value 
Age  
≤ 50 yrs 
> 50 yrs 
 
122      (40.6%) 
178      (59.4%) 
 
134         ( 41.87% ) 
186         (58.13%) 
 
0.76 
Gender: 
Male 
 
165    (55%) 
 
167  (52.19 %) 
 
0.48 
Female 135       (45%) 153  (47.81 %) 
Dwelling: 
Urban 
 
81         (27%) 
 
83            (25.93%) 
 
0.76 
Rural 219       (73%) 237          (74.07%) 
Smoking: 
Smokers 
 
153       (51.0%)           
 
175          (54.68%) 
 
0.35 
Non smokers 147       (49.0%) 145          (45.32%) 
n= No. of individuals; *P using χ2 Test (P<0.05, Data statistically significant) 
Out of 300 cases, 81 (27%) belonged to urban region,219 (73%) to rural ones; 122 (40.6%) were either below or of 50 
years of age, 178(59.4%) were above 50 years of age and 153 (51%) carried out some type of smoking (Hukka or 
Cigarette either singly or in combination) or used to snuff. 157 (52.33%) patients carried the malignancy in colonic 
region and 143 (47.67%) had it in rectal region. It was observed that cases had higher percentage of subjects from rural 
areas, above 50 aged subjects, males and smokers as compared to urban dwellers, below 50 years aged subjects, females 
and non-smokers respectively. 
The status of RCF1 G80A polymorphism in all subjects was addressed by PCR amplification of genomic DNA as 
described in Materialsand Methods section, followed by restriction digestion with an appropriate endonuclease. The 
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results of the amplification are shown in the figure 2. Figure 3 shows the RFLP digestion profile of subjects under study 
for RFC homozygous and heterozygous variants. Table 2 and Table 3distributethe calculated allelic and genotypic 
frequencies of RFC1 gene in cases vs. controls respectively. 
 
Lane           1                  2              3             4                M 
 
   230250 bp 
 
Figure 2: representative gel picture showing the PCR amplification products for RFC gene. Lane no.  1, 2, 3, and 4 represent the PCR 
product size of 230 bps for different subjects. Lane no. M represents the 50 bp ladder. 
 
Lane             1              2              3             4              5               6 
250 bp                  162 bp                                            
                                  125 bp                                                                                                                                          
                37 bp 68 bp 
Figure 3: representative gel picture showing the RFLP results for RFC gene. lane no. 1 represents the 50 bp ladder. Lane no. 2 and 6 
represent the homozygous AA condition. Lane no. 3 represents the heterozygous GA condition. Lane no. 4 and 5 represent the 
homozygous GG condition. 
 
Table 2: Frequency of RFC alleles in CRC patients and controls 
 
 
 
 
ns= No. of Alleles; *P using χ2 test; P<0.05 (Data statistically significant) 
 
ALLELOTYPE Cases 
ns          (%) 
Controls 
ns(%) 
Odds ratio  95% confidence 
interval 
P value 
G 284 (47.33%) 329    (51.4%) Referent     -------- ------- 
A 316 (52.67%) 311   (48.6%) 1.17 0.9418-1.471 0.15 
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From allele typing it was observed that the frequency of RFC G allele was found to be less (47.33%) in cases than 
in(51.4%) controls.While as reverse was seen for the A allele which showed a frequency of 52.67% in cases and 48.6% 
in controls.Cases with A allele showed a 1.17 fold risk in comparison to the wild allele G though the result was not 
statistically significant (P= 0.15). 
Table 3: Distribution of RFC 1 genotypes in colorectal cancer cases and controls. 
Polymorphism 
/ genotype  
Cases 
n    (%) 
Controls 
n (%) 
OddsRatio            
(OR) 
95% Confidence 
Interval(CI) 
P value 
GG 92  (30.67%) 113 (35.32%) Referent          -----     ------ 
GA 100 (33.33%) 103 (32.18%) 1.19 0.8080 - 1.760 0.37 
AA 108  (36.0%) 104 (32.50%) 1.27 0.8678 - 1.875 0.21 
*P using χ2 test; P<0.05 (Data statistically significant) 
On genotypic distribution, the homozygous GG genotype was found to be present in 92(30.67%) of the cases and 113 
(35.32%) of the controls, the heterozygous GA variant was seen in 100 (33.33%) of the cases and 103 (32.18%) of 
controls, and the AA homozygous genotype was detected in 108 (36.0%) of cases and 104 (32.50%) of controls implying 
that the frequency of homozygous AA and heterozygousGA variant was more in colorectal cancer patients than GG 
(wild type) which was more in controls. The most common genotype found in cases was AA and in controls it was GG.   
When stratified for several variable characteristics (Table 4), age group distribution revealed that above 50 age group had 
relatively higher number of the three genotypes (56, 61, and 61 for GG, GA and AA) as compared to below 50 age 
group(GG=36;GA=39;AA=47). When dwelling was taken as a criteria, rural dwellers showed frequencies of 
[GG=71(77.18%); GA= 73(73%) and AA= 75(69.45%)] that were higher than the urban dwellers [GG=21(22.82%); 
GA= 27(27%); AA= 33(30.55%)]. For gender stratification, males showed highest frequency of the AA genotype 
(64.81%) than GG (58.7%) or GA (41%) while as females had GA (59%) as the most predominant genotype followed by 
GG (41.3%) and AA (35.19%). Smokers showed a highest frequency of AA genotype (62.97%) as compared to non-
smokers which had a higher frequency GG (63.05%). P value= 0.001denoted statistical significance. Subjects with 
cancer in colonic region showed AA genotype dominance (72.22%) as compared to subjects with rectal cancer which 
showed higher frequency of GG genotype (57.6%).  
To evaluate the significance of RFC polymorphism individually, we further stratified it in colon cancer patients Table 5 
shows association of RFC variants among the different categories of colon cancer patients. Female colon cancer patients 
showed higher frequency of GG (53.85%) and GA (70%) genotypes while as male patients had higher AA genotype 
(60.26%). Smoking status also showed higher AA genotype frequency (89.74%) for smokers as compared to non-
smokers (10.26%).  
Study showed that there was a similar distribution of urban and rural dwellers among general colorectal cancer and colon 
cancer groups. Majority of the patients came from rural areas. When age of patients (cases) was categorized, two general 
categories (≤50 and >50) were included in the initial analysis to begin with. Subjects above 50 showed higher 
frequencies of GG, GA and AA genotype as compared to below 50 subjects. 
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Table 4:Clinicopathological Characteristics of Colorectal Cancer Patients and RFCA80G Polymorphism 
Variables  Total 
n=300 (%) 
GG 
n=92 (%) 
GA 
n=100 (%) 
AA 
n=108 (%) 
 
χ2, P value 
 
Age  
 
≤ 50 
> 50 
 
122 (40.6%) 
178 (59.4%) 
 
36 (39.13%) 
56 (60.86%) 
 
39 (39 %) 
61 (61%) 
 
47 (43.51%) 
61 (58.48%) 
 
 
0.56, 0.75 
Gender Male 
Female 
165 (55%) 
135 (45%) 
54 (58.7%) 
38 (41.3%) 
41 (41%) 
59 (59%) 
70 (64.81%) 
38 (35.19%) 
12.63, 0.001 
Dwelling Urban 
Rural 
81   (27%) 
219 (73%) 
21 (22.82%) 
71 (77.18%) 
27 (27%) 
73 (73%) 
33 (30.55%) 
75 (69.45%) 
1.50, 0.47 
Smoking Smoker 
Nonsmoker 
153 (51%)           
147 (49%) 
34 (36.95%) 
58 (63.05%) 
51 (51%) 
49 (49%) 
68 (62.97%) 
40 (37.03%) 
13.45, 0.001 
 Location Colon  
Rectum 
157(52.33%) 
143(47.67%) 
39 (42.4%) 
53 (57.6%) 
40 (40%) 
60 (60%) 
78 (72.22%) 
30 (27.78%) 
26.87,0.0001 
 
Table 5: Significance of RFCI Polymorphism with Respect to Characteristics of Colon Cancer Patients 
Variables  Total 
n=157 (%) 
GG 
n=39 (%) 
GA 
n=40 (%) 
AA 
n=78 (%) 
 
χ2, P value 
Gender Male 
Female 
77    (49%) 
80    (51%) 
18 (46.25%) 
21(53.85%) 
12 (30%) 
28 (70%) 
47 (60.26%) 
31 (39.74%) 
9.85, 0.007 
Dwelling Urban 
Rural 
56(35.67%) 
101(64.33%) 
12 (30.77%) 
27 (69.23%) 
15 (37.5%) 
25 (62.5%) 
21 (26.92%) 
57 (73.08%) 
1.39, 0.49 
Smoking Smoker 
Nonsmoker 
120 (76.43%)           
37 (23.57%) 
22 (56.41%) 
17 (43.59%) 
28 (70%) 
12 (30%) 
70 (89.74%) 
8   (10.26%) 
17.27, 0.0002 
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Although our study did not show an overall statistically significant association of RFCpolymorphism with the risk of 
CRC but we found that both the GA heterozygous and the AA homozygous variants showed a 1.19(OR= 1.19, 95%CI, 
0.8080- 1.760) and 1.27 (OR=1.27, 95%CI, 0.8678-1.875) fold increased risk as compared to wild homozygous GG 
genotype. Our study showed statistically significant results when gender, smoking and tumor location characteristics 
were stratified with RFCpolymorphism. Study on contrary showed no significant association between RFC 
polymorphism and age or dwelling among colorectal cancer patients in general or colon cancer in specific.  
 
5. Discussion 
Because of its important role, folate levels affect both DNA repair and gene expression. Folate deficiency leads to large 
scale mis incorporation of uracil into DNA and chromosome breaks. This in turn induces chromosome damage, fragile 
site formation, micronucleus formation and elevated uracil levels in the DNA [35]. Any functional alterations due to 
polymorphisms in the genes involved in folate transport and metabolism may be associated with the development of 
cancers [36]. 
From the critical role of RFC in membrane transport of folates for cellular proliferation and tissue regeneration and of 
antifolates for cancer therapy, interest in RFC gene variants is particularly acute. Also mean expression levels of the 
RFC1 protein have been shown to be higher in tumor tissues compared with normal colonic mucosa [37].Therefore, is 
good candidate for studying the effect of polymorphisms in folate transporting genes on the development of 
malignancies like colorectal cancer. 
Taking this in account, the aim of our study was to assess the RFC polymorphic variants in our population and correlate 
them with CRC susceptibility. We found out that the G allele was more common in the general population in comparison 
A allele was more frequent with a 1.17 fold risk in cases than in controls. Genotypic distribution also showed more of 
homozygous GG and heterozygous GA genotypes in normal population while as homozygous AA genotype showed 
higher distribution in cases. Though the results were not statistically significant however we observed that individuals 
with the AA and GA genotype were at a 1.27 fold and a 1.19 fold increased risk in comparison to individuals containing 
the GG wild genotype. The variant A allele is consistently and linearly associated with higher plasma folate 
concentrations or in other words lesser cellular uptake [38]. 
Arg27 is predicted to lie in the first transmembrane domain, a region implicated as important to carrier function [38-42]. 
This RFC G80A alteration, at position 80 of the coding region results in an amino acid substitution (i.e., Arg/His27). 
Inactivating mutations in the RFC coding region abolish its transport activity, thereby resulting in altered folate uptake 
and antifolate resistance [38, 39] and [43]. Similar to our results have been observed by [24, 26, 44,45].Whether the 
RFC1 80G>A variant induces shifts in intracellular folate redistribution is not known. In addition, other regulating 
factors in cellular folate metabolism might counteract the diminished influx. Thus, patients carrying the RFC1 80A allele 
may have lower folate or methotrexate (MTX) uptake, which might increase cancer risk and decrease MTX efficacy. 
Interestingly, the RFC1 gene is located on chromosome 21. Extra copies of this chromosome in favorable subgroups may 
be associated with enhanced RFC1 mRNA expression and MTX-PG accumulation [46] and, hence, may be a selective 
advantage. 
 
513 
 
 International Journal of Sciences: Basic and Applied Research (IJSBAR)(2014) Volume 14, No  1, pp 506-518  
The association of RFC polymorphism with gender where males had higher frequency of AA (64.81%; 60.26%) and 
females with GA (59%; 70%) genotypes respectively in case of colorectal cancer (χ2 =12.63, P= 0.001) and in colon 
cancer (χ2=9.85,P=0.007) alone points towards complex interactions between gender-related differences in exposure to 
hormones and risk factors, and how they interact with two different kinds of RFC proteins, also observed byCornelia et 
al.(2005)[24]. 
Our study also yielded a positive statistical interaction between the occurrence of colon cancer and RFC polymorphism, 
which was consistent with the studies carried out by Cornelia et al.(2005) [24].We found statistically significant results 
for smoking for RFC polymorphism in CRC patients when stratification was done in general for CRC (χ2=13.45, P= 
0.001) and for colon cancer alone(χ2 = 17.27, P= 0.0002).The reason could be that the large number of individuals of this 
population are relatively high consumers of tobacco (in the form of Hukka for rural and cigarette for urban areas), apart 
from other rich sources of carcinogens suggested to have a strong role to play in the etiology of cancers [47-49].Current 
and former smokers are more likely to develop colorectal cancer than lifelong nonsmokers (defined as smoking fewer 
than 100 cigarettes in their lives). Similar results to ours were shown by [50] and [51]. 
CRC is a complex disease, and both environmental and genetic factors are involved in the development of the disease. 
Our observation thus supports the notion that the effect of single genetic factor (RFC polymorphism in this case) on the 
risk of CRC may be more pronounced in the presence of other common genetic or environmental risk factors such as 
smoking. 
6. Conclusion 
Our study has shown the variants of RFC gene involved in folate transport with respect to CRC patients within a 
homogenous ethnic group. Our study is the first in our knowledge to investigate prospectively the frequency and relation 
of the RFC gene polymorphism with colorectal cancer in Kashmiri population. It was observed that RFC AA variant 
genotype and GA genotype have a 1.27 and 1.19 fold increased risk of CRC respectively. Significant association of RFC 
polymorphism was observed for gender and location of cancer with CRC susceptibility. RFC polymorphism showed 
significant association with CRC in smokers.  
Due to the historical, cultural, religious and lifestyle differences, Kashmiri’s show wide genetic diversities.Also a 
limitation to this study is a limited sample number. Thus, to confirm our findings and to clarify the contribution of this 
gene in the development and prognosis of CRC, more exhaustive studies on a large scale need to be carried out on our 
population. 
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